TNFRSF8 expression

EBV+DLBCL is more prevalent in the elderly and often exhibits aggressive clinical features. The expression of CD30 is not associated with the overall prognosis of EBV+DLBCL.

P2, N=39, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024

P1, N=110, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Recruiting | N=18 --> 110

P2, N=28, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | N=40 --> 28 | Trial completion date: Mar 2026 --> Apr 2030

Our study further underlines that HRS(-like) cells are not pathognomonic of CHL. Since no single pathologic criterion distinguishes TFHL and CHL, an integrative approach ideally comprising molecular investigations is fundamental.

P2, N=170, Recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

The antibody-drug conjugate brentuximab vedotin (BV), targeting CD30-positive cells, has been approved for the treatment of relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (sALCL), and primary cutaneous anaplastic large cell lymphoma or mycosis fungoides in patients who have received previous systemic therapy...A phase III clinical study demonstrated that the combination of BV with cyclophosphamide, doxorubicin, and prednisone (CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for CD30-positive PTCL...We focus on dissecting the underlying mechanisms of BV, discussing its effects on both tumor cells and the tumor microenvironment. Exploring resistance mechanisms in TCL provide valuable insights for optimizing BV-based therapies in the future.

To our best knowledge, this is the first pediatric case of LyP type D with exclusive intraoral involvement.

P1/2, N=146, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Dec 2026

P2, N=52, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2025 --> Apr 2025

P=N/A, N=1000, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jun 2026

Lack of CD2 was also associated with the presence of extramedullary involvement affecting the spleen, liver, and/or lymph nodes (odds ratio 2.63 compared to SM with CD2+ MC). Together, lack of CD2 expression in MC is a prognostic marker and indicator of reduced OS and extramedullary disease expansion in patients with SM.

In the present case, the patient died of multiple organ failure shortly after diagnosis. Lymphoma exhibits an atypical immunophenotype, thus emphasizing the importance of a thorough analysis of the interrelations among clinical, imaging and pathological features.

This review contributes to the growing evidence suggesting that CD30 expression levels do not predict the clinical benefit of BV as the drug demonstrated substantial efficacy in patients across a wide range of CD30 expression levels while suggesting that the antitumor activity was not associated with CD30 expression levels. Furthermore, the potential of BV as a targeted approach along with its mechanism of action is also summarized to explain its key role in the future treatments of lymphomas, especially for CD30-expressing lymphomas.

BV+pembrolizumab in solid tumor malignancies resulted in clinically meaningful, durable responses with encouraging OS and PFS rates supportive of the immunomodulatory activity of this combination. Stronger antitumor activity was observed in secondary refractory cohorts. The safety profile of this combination was consistent with the individual drug risk profiles.

This article reports a patient with peripheral T cell lymphoma following treatment of Hodgkin lymphoma.The biopsy of cervical lymph node initially confirmed classic Hodgkin lymphoma,with Reed-Sternberg cells expressing CD30 and B cell-specific activator.After 2 years,the disease progressed and the patient was diagnosed with peripheral T-cell lymphoma (non-specific type) by lymph node biopsy,with the expression of CD3,CD4,and CD8.The patient was undergoing chemotherapy in November 2023.

The distinctive morphology and immunoprofile of this neoplasm may pose challenges in the differential diagnosis with cutaneous neoplasms showing keratins, ALK, and CD30 immunoreactivity. Nonetheless, ALK and CD30 overexpression may offer avenues for targeted therapy.

P=N/A, N=1006, Completed, Takeda | Active, not recruiting --> Completed | N=2800 --> 1006 | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024

These include single-agent brentuximab vedotin, histone deacetylase inhibitors, duvelisib, ruxolitinib, EZH2 inhibitors, and azacitidine, among others. Follicular helper T-cell lymphomas, given frequent mutations in epigenetic regulator genes, may preferentially respond to agents such as histone deacetylase inhibitors, EZH2 inhibitors, and hypomethylating agents. As these therapies evolve in their use for both relapsed/refractory disease and then into frontline treatment, subtype-specific therapy will likely help personalize care for patients with PTCL.

High RHOF expression demonstrates a superior diagnostic ability in distinguishing PMBL from DLBCL-NOS compared to existing markers. Furthermore, research on RHOF expression in PMBL holds promise for providing new targets and insights for prognosis assessment and treatment of PMBL.

P1, N=18, Active, not recruiting, Seagen Inc. | Recruiting --> Active, not recruiting | N=110 --> 18

This case underscores the importance of early biopsy and molecular testing when standard treatments fail. Early recognition and routine examinations, including lymph node assessments and skin biopsies, are critical for improving patient outcomes, as timely diagnosis leads to more effective treatment options and potential remission.

The promising clinical efficacy observed warrants further investigation, and development of acimtamig for patients with R/R CD30+ lymphomas continues in combination with allogeneic natural killer cells.

The PTCL-TFH cases correlated with an angioimmunoblastic T-cell lymphoma (AITL) gene signature, had more EBER-positive cells than the PTCL-GATA3 and PTCL-TBX21 cases, and a subset had some morphologic features of AITL (p < 0.01). This study highlights the unique morphologic and phenotypic variations within the newly-identified PTCL subtypes and should enable more precise diagnosis and tailored therapeutic strategies in the future.

P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2040 --> Aug 2038 | Trial primary completion date: Aug 2025 --> Sep 2027

Objective: To evaluate the efficacy and safety of brentuximab vedotin (BV) combined with rituximab and attenuated chemotherapy in the treatment of children with classic Hodgkin lymphoma (cHL). At 6 and 9 months of follow-up, IgA, IgG, IgM and total B cell counts returned to pre-chemotherapy baseline levels, respectively. BV combined with rituximab attenuated chemotherapy has demonstrated efficacy and a tolerable safety profile in the treatment of cHL in children, and significantly reduce radiation rate.

Gene expression profiling data have shownthat ALK-negative ALCL has distinctive molecular signatures, different from ALK+ ALCL and other T-cell lymphomas. Better understanding of the morphologic, immunophenotypic, genetic and molecular features of ALK-negative ALCL will help establish the correct diagnosis, guide therapeutic strategies and improve patient outcomes.

Furthermore, CD30 expression in GC B cells promoted the expansion of IgG1-switched cells, which displayed either a GC or memory-like B-cell phenotype, with abnormally high IgG1 levels compared with those in controls. These findings shed light on the role of CD30 signaling in GC B cells and suggest that elevated CD30+ B-cell numbers lead to pathological lymphocyte activation and proliferation.

The patient in case 2 had no other known tumors at the time of diagnosis, but no follow-up is available. We believe the reported cases represent a hitherto unrecognized variant of "NTRK-rearranged spindle cell neoplasms" of the uterine cervix with novel EGFR mutations.

P2, N=78, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Jan 2025 --> Jan 2024

P1/2, N=146, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting

P2, N=82, Active, not recruiting, Seagen Inc. | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> May 2024

In patients with CD30-expressing CTCL, Brentuximab Vedotin has demonstrated better response rates and progression-free survival (PFS); in advanced SS, mogamulizumab has significantly increased PFS. These findings emphasize the need to standardize prognostic factors and improve CTCL treatment.

P2, N=40, Recruiting, University of Washington | Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Sep 2024 --> Mar 2025

The patient whose tumor harbored SEC31A::PDGFRA was treated after multiple relapses with imatinib and sunitinib therapy, with progression-free periods of 5 and 2 years, respectively. Despite its bland appearance, myxoid inflammatory myofibroblastic sarcoma harbors a significant risk for disseminated disease, particularly when it occurs in the peritoneum. Targeted therapy could be considered for patients with disseminated disease.

P=N/A, N=1000, Recruiting, Takeda | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024

P2, N=39, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Dec 2024

The CD30+ expression in DLBCL patients indicates a good prognosis and has certain diagnostic value in evaluating the prognosis of DLBCL patients.

Three cases previously classified as PTCL CD30+CD15+ showed DUSP22/IRF4 rearrangements, favouring a diagnosis of ALCL, ALK-. Our results suggest that cases previously designated PTCL CD30+CD15+, likely fall within the spectrum of ALCL, ALK-; additionally, a subset of ALCL, ALK- with DUSP22/IRF4 rearrangement expresses CD15, consistent with previous reports and expands the immunophenotypic spectrum of this lymphoma subgroup.

GATA3-negative cHL was significantly associated with unfavorable prognostic factors such as older age at diagnosis and increased levels of serum β2-microglobulin. The heterogenous expression patterns of GATA3 in HRS cells that were observed in a substantial proportion of cHL, mainly in the NS subtype, further support the biological heterogeneity of cHL.

Through methods in cell biology and biochemistry, we were able to discover that the second CD30 ligand isoform has no discernable pro-inflammatory function and, in fact, isoform 2 can restrict the capacity of the canonical isoform to signal through the CD30 receptor by preventing their interaction. This discovery has implications for the future development of therapeutics targeting the CD30/CD30 ligand signaling pair in cancer and inflammatory disease.

P2, N=55, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025